# Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC

> **NCT06332755** · PHASE1 · RECRUITING · sponsor: **LG Chem** · enrollment: 76 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer(NSCLC)
- Head and Neck Squamous Cell Carcinoma(HNSCC)
- Renal Cell Carcinoma(RCC)
- Urothelial Carcinoma
- Malignant Melanoma

## Interventions

- **DRUG:** Phase 1a: LB-LR1109
- **DRUG:** Phase 1b: LB-LR1109 and Atezolizumab

## Key facts

- **NCT ID:** NCT06332755
- **Lead sponsor:** LG Chem
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-05
- **Primary completion:** 2027-11
- **Final completion:** 2028-03
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2025-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06332755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06332755, "Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06332755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*